Patents
1) “Antigenic regions of Tumor Liberated Particles (TLP) complexes and antibodies”.
Priority date(s): IT July 7, 1992. Europe: Patent No. EP649433 granted on November 19, 1997 and validated in the following countries: Austria, Belgium, Denmark, France, Germany, Ireland, Nethelands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Eurasia & Asia Australia: Patent No. 680198, granted on 11/13/97; Russian Federation: Patent No. 2141969, granted on 4/21/99; South Korea: Patent No. 237250 granted on 10/10/99. US, Canada, Mexico and Brazil United States: 1) Patent No. 5759792, granted on 6/2/98; 2) Patent No. 5747643, granted on 5/5/98; 3) Patent No. 5877294, granted on 3/2/99; Canada: Patent No. 2139518, (“Notice of allowance” dated 01/10/2003).
2) “Pharmaceutical compositions comprising natural human interferon”
Priority dates: 02/28/1996, 6/14/1996) Patents Issued Europe European Patent No. 0.886.527, granted on 9/12/01: Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Other countries: Australia: Patent No. 722987, granted on November 30, 2000; Eurasia (Armenia, Azerbaijan, Belarrus, Kyrgyzstan, Kazakhstan, Maldava, Tajikistan, Turkmenistan): Patent No. 001147, recently granted (the granting date is not yet available). Georgia: Patent No. 2489, granted on July 25,2001; Italy: 1) Patent No. 1.283.945, granted on May 7, 1998; 2) Patent No. 1.284.852, granted on May 22, 1998. North Korea: Patent No. 33639, granted on December 24, 1999; Russian Federation: Patent No. 001147, recently granted (see “Eurasia”);
3) “Urogenital carcinoma TLP complex peptides and antibodies thereof”.
Priority date(s): IT October 10 1996. Europe: Patent No. EP851872 granted on April 18, 2001 and validated in the following countries: Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom.
4) “Immunogenetic TLP composition”
Priority date(s): IT July 10, 1996. Europe: Patent No. EP938329 granted on May 29, 2002 and validated in the following :Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom. Other countries: Australia: Patent No. 725218, granted on January 25, 2001. Russian Federation: Patent Applications No. 2192274, granted on November 10, 2002.
5) “Sticking plaster for controlled release of natural interferon”
Priority date(s): see PCT application. International Patent Application No. PTC/EP98/03809, filed on June 22,1998, has been extended in the following countries: Australia, Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has expressed a favourable opinion with regard to novelty, inventiveness and industrial applicability. Austria: Patent No. 84396/98 has been allowed and the corresponding Patent issued shortly. New Zelanda: Patent No. 509029 has been allowed and the corresponding Patent issued shortly.
6) “Transdermal pathch and tropical compositions comprising propylnorapomorhine”.
Priority date(s): IT July 17, 1998. International Patent Application No. PTC/IE99/00066, filed on July 15,1999, has been extended in the following countries: Australia, Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has acknowledged the novelty of the claims Japan: Patent Applications No. 2000-559833, filed on January 15, 2001. Mexico: Patent No. 000527, filed on January 15, 2001. Norway: Patent Applications No. 20010248, filed on January 15, 2001.
7) “Use of rubidium and in particular rubidium chloride as an antimaniac agent and stabilizer for mood swings”.
Priority date(s): IE April 19, 1999. International Patent Application No. PTC/IE00/0004, filed on April 17,2000, has been extended, within the terms foreseen by the international conventions, in the following countries: Canada, China, Europe, Japan, Mexico, New Zelanda, Norway, U.S.A. The International Preliminary Examination Report, issued at the end of the PCT procedure, has expressed a favourable opinion with regard to novelty, inventiveness and industrial applicability.
8) “TLP Peptides and DNA-sequences coding the same”.
Priority date(s): IT February 25, 2000. The International Patent Application No. PTC/E001/01857, filed on Februry 20,2001, has been extended, within the terms foreseen by the in ternational conventions, in the following countries: Australia, Brazil, Canada, China, Japan, North Corea, Russian Federation, South Corea, U.S.A. Europe, designating: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland Liechteinstein, Turkey, United Kingdom. The International Preliminary Examination has been concluded (IPER issued on May 21, 2002) with a positive opinion regard to novelty, inventiveness and industrial applicability of the claims concerning the cDNA of TLP, the peptide coded by the same and the relevant pharmaceutical compositions.
9) “Diphenyl ketoaldehyde derivatives with anti-HIV activity”.
Priority date(s): IT March 24, 2000. The International Patent Application No. PTC/EP01/03343, filed on March 23,2001, has been extended, within the terms foreseen by the international conventions, in the following countries: Australia, Brazil, Canada, China, Japan, Mexico, New Zelanda, Norway, Russian Federation, South Africa, U.S.A. Europe, designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland/Liechteinstein, Turkey, United Kingdom. The International Preliminary Examination Report, issued at the end of the PCT procedure, has acknowwledged the novelty of the invention.
10) “Compounds with anti-Rhinovirus activity”.
Italy: The Patent Application filed on June 9,2000 under No. MI2000A001288, has not been extended.
11) “Slow release” pharmaceutical compositions comprising lithium carbonate.
Priority Date(s): IT August 6, 2001.
Priority: IT/10.08.00/ITA MI001868 + IT/14.O2.01/MI000299. Designated states: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR.
The International Patent Application No. PTC/EP01/09054, filed on August 6,2001, and extended, within the term foreseen by the international conventions, in the following countries: Europe, designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden, Switzerland/Liechteinstein, Turkey, United Kingdom, and moreover in: “Euroasiatic Area”, designating the following countries: Armenia, Azerbaijan, Belarrus, Russian Federation, Kyrgyzstan, Kazakhstan, Maldava, Tajikistan, Turkmenistan. Australia, Brazil, Canada, China, Japan, U.S.A. On October 2, 2002, the IPER (International Preliminary Examination Report), has expressly acknowledged novelty, inventiveness and industrial applicability of all the five claims.
12) “TLP Antigen and diagnostic applications thereof”.
Priority Date (s): IT, June 29,2001.The International Patent Application No. PTC/EP02/07020, filed on June 25, 2002, has been published on January 9, 2003 under No. WO03/002591.The international preliminary examination concluded within October 29, 2003, while the national/regional started within December 29, 2003.
13) “Fusion Proteins containing TLP peptides”.
Priority Date (s): IT, November 30, 2001. The International Patent Application No. PTC/EP02/13470 has been filed on November 29, 2002.
14) “Compounds with anti-Rhinovirus activity”.
The Italian Patent Application (No. MI2002A000966), filed on May 8, 2002, extended within the priority year as PTC application.
Date (s): December 13, 2004. Application No./Patent No.: 03727431.3-2123-EP0304673. Date of filing: May 5, 2003. Priority: IT/08.05.02/ITA MI20020966. Designated states: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR.
15) “Pharmaceutical composition containing the association LevodopaCarbidopa”.
Italian Application filed on April 18, 2003.
16) “Pharmaceutical compositions containing interferon f or the treatment of Human Papilloma Virus Infections”.
Italian Application filed on April 18, 2003.
17) “Method of treating viral hepatitis by administration of liquid human α-interferon”
Issued on April 26, 2005 Patent 6884411 – US classes
